Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.” - Art exhibit at University of Miami Sylvester bridges North and South America
- Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate
- The Human Tumor Atlas Network charts the roadmap for advancing spatial omics
- VCU awarded $9M from NCI to establish Cancer Control Equity Research Center
- The Cancer Letter’s most-read stories of 2024